ArticleOncoimmunology
Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 69 citations in OpenAlex.
- Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration.Nature communications · 2026Article
- Activation of the C3a-C3aReceptor-axis is associated with endothelial dysfunction and glycocalyx damage in ST-elevation myocardial infarction.Basic research in cardiology · 2026Article
- Tumour-associated vasculature in T cell homing and immunity: opportunities for cancer therapy.Nature reviews. Immunology · 2025Review
- The role of the complement system in the response to cytotoxic therapy.Seminars in immunology · 2025Review
- Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy.Heliyon · 2024Review
- B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.Journal for immunotherapy of cancer · 2024Review
- Aberrant tumor vasculature. Facts and pitfalls.Frontiers in pharmacology · 2024Review
- "Cold" colorectal cancer faces a bottleneck in immunotherapy.World journal of gastrointestinal oncology · 2023Review
- "Open Sesame" to the complexity of pattern recognition receptors of myeloid-derived suppressor cells in cancer.Frontiers in immunology · 2023Review
- Comprehensive analysis of complement-associated molecular features in hepatocellular carcinoma.Acta biochimica et biophysica Sinica · 2022Article
- Role of Suprabasin in the Dedifferentiation of Follicular Epithelial Cell-Derived Thyroid Cancer and Identification of Related Immune Markers.Frontiers in genetics · 2022Article
- Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.Journal for immunotherapy of cancer · 2021Article
- Review
- Mechanisms Driving Neutrophil-Induced T-cell Immunoparalysis in Ovarian Cancer.Cancer immunology research · 2021Observational
- Antiphospholipid syndrome: Complement activation, complement gene mutations, and therapeutic implications.Journal of thrombosis and haemostasis : JTH · 2021Review
- Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression.Journal for immunotherapy of cancer · 2021Article
- Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.Clinical immunology (Orlando, Fla.) · 2020Article
- Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target.JCI insight · 2020Article
- Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy.International journal of molecular sciences · 2020Review
- Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.Antibodies (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
Abstract
Cancer immunotherapy relies upon the ability of T cells to infiltrate tumors. The endothelium constitutes a barrier between the tumor and effector T cells, and the ability to manipulate local vascular permeability could be translated into effective immunotherapy. Here, we show that in the context of adoptive T cell therapy, antitumor T cells, delivered at high enough doses, can overcome the endothelial barrier and infiltrate tumors, a process that requires local production of C3, complement activation on tumor endothelium and release of C5a. C5a, in turn, acts on endothelial cells promoting the upregulation of adhesion molecules and T-cell homing. Genetic deletion of C3 or the C5a receptor 1 (C5aR1), and pharmacological blockade of C5aR1, impaired the ability of T cells to overcome the endothelial barrier, infiltrate tumors, and control tumor progression
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.